Cellectis S.A. (CLLS)
CLLS trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$1.10
-6.78% on the day
Market cap
$110.6M
Micro cap
Revenue · 2025
$72.9M
No prior year to compare
Net income · 2025
-$67.6M
-92.7% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC 20-F (ifrs-full:Revenue), period ending 2025-12-31, https://www.sec.gov/Archives/edgar/data/1627281/000119312526116428/0001193125-26-116428-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLossAttributableToOwnersOfParent), period ending 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | CLLS on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | France |
| IPO year | 2015 |
| SEC CIK | 0001627281 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | I0 |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $72.9M |
| Net income | -$67.6M |
| Operating income | Not in SEC XBRL data |
| Net margin | -92.7% |
| Operating margin | Operating income not reported |
| Revenue growth | No prior-year revenue to compare |
| Cash | Not in SEC XBRL data |
| Total assets | Not in SEC XBRL data |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 1.5× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | F-3 | 2025-07-02 |
| Latest annual report | 20-F | 2026-03-20 |
| Latest quarterly / interim FORM 6-K | 6-K | 2026-09-14 |
Source: SEC EDGAR submissions feed, 533 recent filings. All filings on EDGAR.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| FHTX | Foghorn Therapeutics Inc. | $1.85 | -5.13% | $109.9M |
| VTVT | vTv Therapeutics Inc. | $28.23 | -7.32% | $111.6M |
| CPIX | Cumberland Pharmaceuticals Inc. | $7.17 | +2.43% | $107.4M |
| GNLX | Genelux Corporation | $2.52 | -0.98% | $114.0M |
| HURA | TuHURA Biosciences Inc. | $1.81 | -4.74% | $115.3M |
| PDSB | PDS Biotechnology Corporation | $1.60 | +5.26% | $116.0M |
| SPRB | Spruce Biosciences Inc. | $40.35 | -5.88% | $116.0M |
| TNXP | Tonix Pharmaceuticals Holding Corp. | $6.13 | -7.68% | $105.1M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier